Loading data for KMDA — first visit, this takes a few seconds.
Kamada Ltd. (KMDA)
NasdaqGS: KMDA
· Real-Time Price · USD
8.53
-0.10 (-1.16%)
At close: Aug 26, 2026, 2:38 PM
The price, the headline numbers and the latest news, in one place.
Kamada Ltd. (KMDA) Stock Price, Analysis & Data
-1.16% (1D)
No data available
| Bid | 6.09 |
| Market Cap | 492.13M |
| Revenue (ttm) | 191.85M |
| Net Income (ttm) | 22.25M |
| 0.13 | |
| 0.38 | |
| 22.45 | |
| 14.3 | |
| P/B (ttm) | 1.83 |
| P/S (ttm) | 2.57 |
| Earnings Date | May 17, 2022 |
| Ask | 10.88 |
| Volume | 109,931 |
| Avg. Volume (20D) | 72,471 |
| Open | 8.56 |
| Previous Close | 8.63 |
| Day's Range | 8.45 - 8.64 |
| 52-Week Range | 6.50 - 9.35 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $0.17 (1.97%) |
| Ex-Dividend Date | Aug 27, 2026 |
About KMDA
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recur...
Sector Healthcare
IPO Date May 31, 2013
Employees 462
Stock Exchange NasdaqGS
Ticker Symbol KMDA
Website https://www.kamada.com
Financial Performance
In 2025, Kamada's revenue was 180.46M, an increase of 12.12% compared to the previous year's 160.95M. Earnings were 20.2M, an increase of 39.66%.
Financial StatementsEarnings Surprise
Kamada has released their quarterly earnings on Aug 12, 2026:
- Revenue of $45.24M misses estimates by $0, with 2.78% YoY growth.
- EPS of 0.16 exceeds estimates by 0.05, with 23.08% YoY growth.
Kamada Ltd. is scheduled to release its earnings on May 17, 2022, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2